eGenesis to Participate in the Virtual U.S. Bancorp | BTIG Kidney Health Forum with Panel Discussion and Investor Meetings

President and CEO Mike Curtis, Ph.D., to Join Panel Discussion on Innovation in Kidney Transplantation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--eGenesis, Inc. (eGenesis), a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced that it will participate in the Virtual U.S. Bancorp | BTIG Kidney Health Forum on October 14, 2026, which will include a panel discussion and one-on-one investor meetings with members of its management team.

eGenesis President and CEO Mike Curtis, Ph.D., will join the panel discussion, titled “Kidney Transplantation: Innovation on the Frontier,” which is scheduled for 10:00 to 10:50 a.m. ET, and a webcast will be available here.

About eGenesis

eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company’s proprietary genome engineering platform enables multiplex gene editing designed to address key barriers to xenotransplantation, including immune rejection and pathogen safety. EGEN-2784, a genetically engineered porcine kidney, is the Company’s lead program. eGenesis is also developing products for liver and heart failure. To date, the Company has received FDA clearance to conduct clinical studies across its kidney and liver programs. eGenesis is headquartered in Cambridge, MA. For more information, visit www​.ege​n​e​sis​bio​.com.